M
Martin Müller
Researcher at German Cancer Research Center
Publications - 156
Citations - 7013
Martin Müller is an academic researcher from German Cancer Research Center. The author has contributed to research in topics: Myeloid leukemia & Imatinib mesylate. The author has an hindex of 44, co-authored 156 publications receiving 6261 citations. Previous affiliations of Martin Müller include Heidelberg University & Hammersmith Hospital.
Papers
More filters
Journal ArticleDOI
Carrageenan Is a Potent Inhibitor of Papillomavirus Infection
Christopher B. Buck,Cynthia D. Thompson,Jeffrey N. Roberts,Martin Müller,Douglas R. Lowy,John T. Schiller +5 more
TL;DR: Comparison of a variety of compounds revealed that carrageenan, a type of sulfated polysaccharide extracted from red algae, is an extremely potent infection inhibitor for a broad range of sexually transmitted HPVs.
Journal ArticleDOI
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
Susanne Saussele,Johan Richter,Joelle Guilhot,Franz Gruber,Henrik Hjorth-Hansen,Antonio Almeida,Jeroen Janssen,Jiri Mayer,Perttu Koskenvesa,Panayiotis Panayiotidis,Ulla Olsson-Strömberg,Joaquin Martinez-Lopez,Philippe Rousselot,Hanne Vestergaard,Hans Ehrencrona,Veli Kairisto,Katerina Machova Polakova,Martin Müller,Satu Mustjoki,Marc G. Berger,Alice Fabarius,Wolf-Karsten Hofmann,Andreas Hochhaus,Markus Pfirrmann,Francois-Xavier Mahon,Gert J. Ossenkoppele,Maria Pagoni,Stina Söderlund,Martine Escoffre-Barbe,Gabriel Etienne,Jolanta Dengler,Françoise Huguet,Nikolas von Bubnoff,Hana Klamova,Edgar Faber,François Guilhot,Kourosh Lotfi,Delphine Rea,Tim H. Brümmendorf,Gorgine E. de Greef,Leif Stenke,Franck E. Nicolini,Laurence Legros,Andreas Burchert,Jaroslava Voglová,Aude Charbonnier,Emmanuel Gyan,Volker Kunzmann,Peter E. Westerweel +48 more
TL;DR: In this paper, a prospective, non-randomised trial was conducted at 61 European centres in 11 countries to investigate the impact of stopping TKI therapy on the survival of patients with chronic myeloid leukaemia.
Journal ArticleDOI
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial
Jorge E. Cortes,Dong-Wook Kim,Javier Pinilla-Ibarz,Philipp le Coutre,Ronald Paquette,Charles Chuah,Franck E. Nicolini,Jane F. Apperley,H. Jean Khoury,Moshe Talpaz,Daniel J. DeAngelo,Elisabetta Abruzzese,Delphine Rea,Michele Baccarani,Martin Müller,Carlo Gambacorti-Passerini,Stephanie Lustgarten,Victor M. Rivera,Frank G. Haluska,François Guilhot,Michael W. Deininger,Andreas Hochhaus,Timothy P. Hughes,Neil P. Shah,Hagop M. Kantarjian +24 more
TL;DR: The final PACE results demonstrate ponatinib provides durable and clinically meaningful responses, irrespective of dose reductions, in this population of heavily pretreated CP-CML patients.
Journal ArticleDOI
Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Rüdiger Hehlmann,Michael Lauseker,Susanne Jung-Munkwitz,Armin Leitner,Martin Müller,Nadine Pletsch,Ulrike Proetel,Claudia Haferlach,Brigitte Schlegelberger,Leopold Balleisen,Mathias Hänel,Markus Pfirrmann,Stefan W. Krause,Christoph Nerl,Hans Pralle,Alois Gratwohl,Dieter K. Hossfeld,Joerg Hasford,Andreas Hochhaus,Susanne Saußele +19 more
TL;DR: Early high-dose therapy followed by rapid adaptation to good tolerability increases the rate of major molecular remission (MMR) at 12 months, and achievement of MMR by month 12 is directly associated with improved survival.
Journal ArticleDOI
Impact of Baseline BCR-ABL Mutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
Timothy P. Hughes,Giuseppe Saglio,Susan Branford,Simona Soverini,Dong-Wook Kim,Martin Müller,Giovanni Martinelli,Jorge E. Cortes,Lan Beppu,Enrico Gottardi,Dongho Kim,Philipp Erben,Yaping Shou,Ariful Haque,Neil Gallagher,Jerald P. Radich,Andreas Hochhaus +16 more
TL;DR: For most patients with imatinib resistance and with mutations, nilotinib offers a substantial probability of response, however, mutational status at baseline may influence response.